ARTICLE | Distillery Therapeutics
Blocking NLRP3 deubiquitination for inflammasome-associated disease
April 30, 2021 7:27 PM UTC
DISEASE CATEGORY: Autoimmune; hepatic; infectious; inflammation
INDICATION: Multiple sclerosis (MS); liver disease; sepsis; inflammation...
BCIQ Company Profiles
BCIQ Target Profiles
NLR family pyrin domain containing 3 (NLRP3) (NALP3) (CIAS1)